ACTR-AD1 2L

ACTR-AD1 2L (10 nM) binds the purified CBP-NCBD domain, full-length recombinant CBP, and full-length recombinant p300 with high affinity, exhibiting K_d values of 6.8 nM, 8.1 nM, and 5.3 nM, respectively^[1].
ACTR-AD1 2L (5 mM; 20 min) enhances the in vitro histone acetyltransferase activity of purified full-length CBP and p300 on histone H3, increasing acH3K27 and acH3K18 levels by up to 2-fold and 1.7-fold, respectively^[1].
ACTR-AD1 2L (10 μM; 1.5 h) modulates the CBP interactome in MCF-7 cells, reducing associations with proteins critical for breast cancer cell growth and altering pathways involved in gene expression and metabolism^[1].
ACTR-AD1 2L (5 μM; 48-96 h) exerts antiproliferative activity in MCF-7 cells, reducing cell number by ~50% at 96 h in both vehicle- and E2-treated conditions^[1].
ACTR-AD1 2L (5 μM; 6 h) reduces cellular histone acetylation in MCF-7 cells, significantly lowering H3K18ac and H4K8ac levels in both basal and E2-stimulated conditions, and H3K27ac levels in E2-stimulated conditions^[1].
ACTR-AD1 2L (5 μM) disrupts the endogenous CBP-NCOA3 complex in MCF-7 cells, reducing the association between the two proteins^[1].
ACTR-AD1 2L (5 μM) modulates E₂-dependent transcriptional programs in MCF-7 cells, downregulating genes involved in gene expression, RNA processing, and metabolic pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.